Abide begins dosing in Phase Ia trial of endocannabinoid system modulator ABX-1431
Around 60 healthy volunteers will be enrolled in the randomized, double-blinded, placebo-controlled Phase I trial, which is currently underway in Belgium. The company said that potential indications for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.